Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria

Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria

The majority of deaths from malaria are in young African children. Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria. Since 2015, the World Health Organization has recommended individual doses of 3 mg/kg for children weighing

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacology and therapeutics 2023-12, Vol.114 (6), p.1304-1312
Hauptverfasser: Haghiri, Ali, Price, David J, Fitzpatrick, Phoebe, Dini, Saber, Rajasekhar, Megha, Fanello, Caterina, Tarning, Joel, Watson, James, White, Nicholas J, Simpson, Julie A
Format: Artikel
Sprache:eng
Schlagworte:
Administration, Intravenous
Adolescent
Antimalarials - adverse effects
Artesunate - therapeutic use
Bayes Theorem
Child
Humans
Malaria - drug therapy
Malaria, Falciparum - drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The majority of deaths from malaria are in young African children. Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria. Since 2015, the World Health Organization has recommended individual doses of 3 mg/kg for children weighing
ISSN:0009-9236
1532-6535
1532-6535
DOI:10.1002/cpt.3041